Stock PFE PFIZER, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pfizer, Inc.

Equities

PFE

US7170811035

Market Closed - Nyse
Other stock markets
 04:01:39 2024-06-10 pm EDT 		After market 05:59:52 pm
28.07 USD -1.78% Intraday chart for Pfizer, Inc. 28.12 +0.18%
11:49pm Latest trial over Zantac cancer claims called off as plaintiff drops case RE
09:34pm Pfizer to Pause Sizable Acquisitions as it Integrates Existing Investments, CEO Says MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company has a good ESG score relative to its sector, according to Refinitiv.

Strengths

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company returns high margins, thereby supporting business profitability.
  • This company will be of major interest to investors in search of a high dividend stock.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's enterprise value to sales, at 3.65 times its current sales, is high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PFIZER, INC. Stock Pfizer, Inc.
-2.50% 162B
C+
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+48.39% 765B
C+
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.13% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.61% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.00% 299B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.87% 248B
B+
ROCHE HOLDING AG Stock Roche Holding AG
-1.96% 219B
A+
NOVARTIS AG Stock Novartis AG
+11.11% 216B
B-
AMGEN INC. Stock Amgen Inc.
+5.80% 164B
C+
SANOFI Stock Sanofi
+0.57% 123B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PFE Stock
  4. Ratings Pfizer, Inc.